INTRODUCTION: This study aims to test the serum levels of interleukin-33 (IL-33) and soluble ST2 (sST2) in patients with chronic kidney disease (CKD) and to evaluate their association with disease severity. METHODS: Sixty-nine patients with CKD were enrolled, disease severity was assessed, and clinical data were collected. Twelve healthy volunteers served as healthy individuals. Serum IL-33 and sST2 were tested by enzyme-linked immunosorbent assay. RESULTS: The patients were classified into five categories based on their estimated glomerular filtration rate (eGFR). No difference was found as to the serum concentration of IL-33 between CKD patients and healthy individuals (p = 0.656), while a higher serum level of sST2 was found in CKD patients (p = 0.003). The correlation analysis revealed a significant correlation between the serum level of sST2 and disease severity (r = 0.586; p < 0.001). A higher level of sST2 was found in CKD patients with elevated parathyroid hormone (p = 0.001). Serum sST2 correlated with parathyroid hormone (r = 0.412; p < 0.001), serum phosphorus (r = 0.545; p < 0.001), and serum calcium (r = -0.494; p < 0.001). CONCLUSION: An elevated concentration of serum sST2 is found in CKD patients and correlates with disease severity. Serum sST2 may be also associated with parathyroid hormone disorder of CKD. The sST2 may have an important role in the development of CKD or as a marker of disease severity.
INTRODUCTION: This study aims to test the serum levels of interleukin-33 (IL-33) and soluble ST2 (sST2) in patients with chronic kidney disease (CKD) and to evaluate their association with disease severity. METHODS: Sixty-nine patients with CKD were enrolled, disease severity was assessed, and clinical data were collected. Twelve healthy volunteers served as healthy individuals. Serum IL-33 and sST2 were tested by enzyme-linked immunosorbent assay. RESULTS: The patients were classified into five categories based on their estimated glomerular filtration rate (eGFR). No difference was found as to the serum concentration of IL-33 between CKDpatients and healthy individuals (p = 0.656), while a higher serum level of sST2 was found in CKDpatients (p = 0.003). The correlation analysis revealed a significant correlation between the serum level of sST2 and disease severity (r = 0.586; p < 0.001). A higher level of sST2 was found in CKDpatients with elevated parathyroid hormone (p = 0.001). Serum sST2 correlated with parathyroid hormone (r = 0.412; p < 0.001), serum phosphorus (r = 0.545; p < 0.001), and serum calcium (r = -0.494; p < 0.001). CONCLUSION: An elevated concentration of serum sST2 is found in CKDpatients and correlates with disease severity. Serum sST2 may be also associated with parathyroid hormone disorder of CKD. The sST2 may have an important role in the development of CKD or as a marker of disease severity.
Authors: Mo Yin Mok; Fang Ping Huang; Wai Ki Ip; Yi Lo; Fung Yi Wong; Eric Yuk Tat Chan; Kwok Fai Lam; Damo Xu Journal: Rheumatology (Oxford) Date: 2009-12-21 Impact factor: 7.580
Authors: Peter N Pushparaj; Hwee Kee Tay; Shiau Chen H'ng; Nick Pitman; Damo Xu; Andrew McKenzie; Foo Y Liew; Alirio J Melendez Journal: Proc Natl Acad Sci U S A Date: 2009-06-08 Impact factor: 11.205
Authors: Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay Journal: Arthritis Rheum Date: 2009-03
Authors: Geun Ho Park; Helen Ki Shinn; Ju-Hee Kang; Won Ju Na; Young Hyo Kim; Chang-Shin Park Journal: Int Neurourol J Date: 2016-06-24 Impact factor: 2.835
Authors: Jozine M ter Maaten; Mattia A E Valente; Marco Metra; Noemi Bruno; Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Gad Cotter; Beth Davison; John G Cleland; Michael M Givertz; Daniel M Bloomfield; Howard C Dittrich; Dirk J van Veldhuisen; Hans L Hillege; Kevin Damman; Adriaan A Voors Journal: Clin Res Cardiol Date: 2015-08-18 Impact factor: 5.460